Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 6, 2006, Pages 465-471

  Roehl, Kimberly A ^a   Eggener, Scott E ^b   Loeb, Stacy ^b   Smith, Norm D ^b   Antenor, Jo Ann V ^a   Catalona, William J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms; Radical prostatectomy; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CALCULATION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GLEASON SCORE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT REFERRAL; PHYSICIAN; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; STANDARDIZATION; SURGEON; TREATMENT OUTCOME;

AGED; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; SURVIVAL ANALYSIS;

EID: 33751326816     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.11.039     Document Type: Article

References (21)

1. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 174 (2005) 121-125
2. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance series: Interpreting trends in prostate cancer-Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91 (1999) 1017-1024
3. Tarone R.E., Chu K.C., and Brawley O.W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11 (2000) 167-170
4. Paquette E.L., Sun L., Paquette L.R., et al. Improved prostate cancer-specific survival and other disease parameters: Impact of prostate-specific antigen testing. Urology 60 (2002) 756-759
5. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
6. Nicholson P.W., and Harland S.J. Survival prospects after screen-detection of prostate cancer. BJU Int 90 (2002) 686-693
7. Walsh P.C., Lepor H., and Eggleston J.C. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4 (1983) 473-485
8. Smith D.S., Humphrey P.A., and Catalona W.J. The early detection of prostate carcinoma with prostate specific antigen: The Washington University experience. Cancer 80 (1997) 1852-1856
9. Weinmann S., Richert-Boe K.E., Van Den Eeden S.K., et al. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: A case-control study. Epidemiology 16 (2005) 367-376
10. Jacobsen S.J., Bergstralh E.J., Katusic S.K., et al. Screening digital rectal examination and prostate cancer mortality: A population-based case-control study. Urology 52 (1998) 173-179
11. American Cancer Society. Cancer facts and figures 2005 (2005), American Cancer Society, Atlanta, (GA)
12. Lu-Yao G., Albertsen P.C., Stanford J.L., et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325 (2002) 740
13. Shaw P.A., Etzioni R., Zeliadt S.B., et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 160 (2004) 1059-1069
14. Perron L., Moore L., Bairati I., et al. PSA screening and prostate cancer mortality. CMAJ 166 (2002) 586-591
15. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417-424
16. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
17. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
18. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
19. Ohori M., Wheeler T.M., Dunn J.K., et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714-1720
20. Krumholtz J.S., Carvalhal G.F., Ramos C.G., et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60 (2002) 469-473
21. Pinsky P.F., Andriole G.L., Kramer B.S., et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 173 (2005) 746-750